What is NMN?
NMN stands for nicotinamide mononucleotide, a naturally occurring molecule in the body that acts as a direct biochemical precursor of NAD+. It belongs to the family of vitamin B3 derivatives and is found in very small amounts in foods such as broccoli, edamame, avocado, and tomatoes. However, the amounts from diet are negligible compared to the concentrations studied in clinical trials.
What has brought NMN into the focus of longevity research is its biochemical position: it lies immediately before the end product in NAD+ biosynthesis. While other NAD+ precursors like nicotinamide riboside (NR) must first be converted into NMN, NMN can enter the final synthesis step more directly. This makes it the biochemically closest available precursor to NAD+.
Why NAD+ becomes more important with age
NAD+ is not a vitamin supplement or a dietary supplement. It is an endogenous coenzyme found in every living cell, where it fulfills two central functions. First, it serves as an electron carrier in the mitochondrial respiratory chain, contributing to ATP production, i.e., the cell’s energy supply. Second, it is an indispensable substrate for sirtuin enzymes (SIRT1 to SIRT7), which regulate gene expression, DNA repair, and the cell’s stress response as NAD+-dependent deacetylases. [1]
The critical point: from the third decade of life, the cellular NAD+ level continuously decreases. By the age of 60, it is only about half the youthful level in many tissues. The causes are well understood. Two enzymes play a major role: PARP-1, a DNA repair enzyme, consumes more and more NAD+ as cell damage increases. CD38, an enzyme active in the immune system, also increases its activity with age and enzymatically breaks down NAD+. [2]
The result is a biochemical deficit that affects multiple systems: less sirtuin activity means poorer DNA repair and stress resistance, less ATP production in the mitochondria means less cellular energy, and both together are closely linked to what we perceive as age-related decline in performance.
How NMN works in the body
The metabolic pathway from NMN to NAD+ is well characterized. After oral intake, NMN is absorbed, enters the circulation through the intestine, and is converted intracellularly into NAD+ in a single step by the enzyme NMNAT (nicotinamide mononucleotide adenylyltransferase). This direct pathway has long been described as a particular advantage of NMN over NR.
A relevant finding from 2026 has nuanced this picture. Christen et al. showed in Nature Metabolism that after oral intake, NMN is initially converted by the gut microbiota into nicotinic acid (NA). The nicotinic acid then enters the bloodstream and increases NAD+ levels there via the so-called Preiss-Handler pathway. [9] This means: NMN is orally biologically active and reliably increases NAD+, but the direct pathway via NMNAT in the gut may play a smaller role than previously thought. The clinical efficacy remains unaffected.
Increased NAD+ activates the sirtuin enzymes, especially SIRT1 and SIRT3, histone deacetylases with far-reaching effects on mitochondrial function, fatty acid oxidation, and cellular stress response. In animal models, long-term NMN supplementation led to improved mitochondrial function, increased physical performance, and reduced age-associated weight gain. [4]
What clinical studies in humans show
The crucial question is whether the impressive effects seen in animal models are reproducible in humans. Several controlled human studies are now available. The overall picture is positive but with clear limitations.
The first published human study came from Irie et al. in Japan. Ten healthy older men received NMN in ascending doses. The result was especially important for safety assessment: no substance-related side effects, measurable increases in blood NAD+, and indications of improved muscle strength and walking speed. As an open pilot study without a control group, it could not provide causal statements but laid the foundation for larger RCTs. [5]
The methodologically most important evidence for metabolic effects to date was provided by a study by Yoshino et al. in Science. Twenty-five premenopausal women with overweight or prediabetes received 250 mg of NMN daily for ten weeks. Not only was the NAD+ level measured, but insulin sensitivity was directly assessed in skeletal muscle cells through a euglycemic clamp test. The result: significantly improved insulin sensitivity and a more favorable gene expression profile in muscle tissue. [6] This study is particularly valuable methodologically because it measured a clinically relevant endpoint directly in the target tissue, not just a surrogate marker (blood NAD+).
The most extensive NMN study in humans to date is the multicenter double-blind study by Yi et al., published in 2023 in GeroScience. 80 healthy adults aged 40 to 65 received 300, 600, or 900 mg NMN daily for 60 days. All three doses significantly and dose-dependently increased blood NAD+ levels compared to placebo. Additionally, the 6-minute walk test improved in all NMN groups. [7] This is the most robust evidence for functional effects from the current human literature.
Another study by Igarashi et al. in NPJ Aging examined 48 older men who received 1,000 mg NMN daily for twelve weeks. Walking speed and grip strength improved significantly compared to placebo. The sample was small and exclusively male, limiting generalizability. [8]
The first direct comparison between NMN, NR, and nicotinamide in humans was provided by Christen et al. in January 2026 in Nature Metabolism. In a 4-arm RCT with 65 healthy adults, NMN and NR increased circulating NAD+ levels comparably after 14 days. Nicotinamide showed only a transient acute effect. [9] Limitations: The study was funded by Nestlé Research, lasted only 14 days, and measured NAD+ increase as a surrogate marker without clinical endpoints.
What is not yet proven
Despite all the positive evidence, a clear assessment is important. Clinically proven are: dose-dependent NAD+ increase in blood, improved insulin sensitivity in a specific population, and improvements in mobility parameters of older adults. All studies have sample sizes of 10 to 80 participants and durations of no more than three months.
Not proven in humans are: a direct effect on lifespan or biological age, prevention of heart disease, protection against dementia or improvement of cognitive functions, and cancer prevention. These goals are biologically plausible because NAD+ is involved in mechanisms that regulate all these processes. However, plausibility is not clinical proof. [10]
State of evidence
An honest assessment of the data based on verified studies:
| Level of evidence | Study type / population | Finding | Assessment |
|---|---|---|---|
| Human studies | RCT, n=80, 40–65 years | 300, 600, 900 mg NMN over 60 days: dose-dependent blood NAD+ increase, 6-minute walk test improved in all NMN groups. (Yi et al. 2023, GeroScience) | 🟢 Strong, placebo-controlled, multicenter |
| Human studies | RCT, n=25, premenopausal women | 250 mg NMN over 10 weeks: improved insulin sensitivity in skeletal muscle cells, more favorable gene expression profile. (Yoshino et al. 2021, Science) | 🟢 Strong, high-ranking publication |
| Human studies | RCT, n=65, 4-arm | NMN increases blood NAD+ comparable to NR after 14 days. Mechanism: Preiss-Handler via gut flora conversion to nicotinic acid. (Christen et al. 2026, Nat Metab) | 🟢 Strong, first direct comparison NMN vs. NR |
| Human studies | Open-label, n=10 | First human study: NMN safe and well tolerated, dose-dependent NAD+ increase without side effects. (Irie et al. 2020, Endocrine J) | 🟡 Moderate, no control group |
| Human studies | RCT, n=48, older men | 1,000 mg NMN: improved walking speed and grip strength vs. placebo after 12 weeks. (Igarashi et al. 2022, NPJ Aging) | 🟡 Moderate, small sample |
| Animal model | Mouse study, aging animals | NMN increases NAD+, improves energy metabolism, muscle strength, body weight. (Mills et al. 2016, Cell Metab) | 🟡 Limited, transferability open |
| Mechanistic | Biochemistry / In vitro | NAD+ activates sirtuin enzymes for DNA repair and mitochondrial function. PARP and CD38 consumption explain NAD+ decline with age. | 🔵 Basis, explains mechanism |
| Gaps | Missing data | No long-term studies over 6 months. No direct longevity evidence in humans. Effect on heart health and cognition in humans not proven. | 🔴 Open, further research needed |
🟢 Strong human study evidence · 🟡 Moderate or limited evidence · 🔵 Mechanistic basis · 🔴 Missing data
Dosage and practical notes
The NMN dosages used in clinical studies range from 250 to 1,000 mg daily; the study situation regarding dose-response and substance-specific recommendations for different age groups is complex. In most studies, NMN was taken in the morning, usually with a meal.
Quality criteria when buying: lab-tested purity over 98%, current analysis certificates from an ISO 17025 accredited lab, light-protected storage. NMN is among the most frequently counterfeited supplements; a detailed buying guide with a quality checklist can be found in the purchase guide.
NMN in the context of other longevity approaches
NMN addresses a specific and well-understood aspect of cellular aging: the decline of NAD+. It acts on mitochondria and DNA repair via the sirtuin pathway but does not directly increase mitophagy or activate other cellular cleaning processes. In this respect, NMN complements substances like Urolithin A, which specifically breaks down damaged mitochondria, or Spermidine, which stimulates general autophagy. The mechanisms hardly overlap, making a combination biochemically sensible.
NMN should not be confused with NR (Nicotinamide Riboside): Both increase NAD+, but NMN has a broader study base for muscle and metabolic effects, while NR scores with direct skeletal muscle tissue data. In practice, the choice between the two is less crucial than the question of product quality and consistent intake.
